CoChat
Sign Up
Cited by 214Nausea and vomiting managementPregnancy and Medication ImpactCancer survivorship and care

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

Meiri, Eyal, Jhangiani, Haresh, Vredenburgh, James J., Barbato, Luigi M., Carter, Frederick J., Yang, Hwa-Ming, Baranowski, Vickie·2007·Current Medical Research and Opinion
DOI 10.1185/030079907x167525
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study. RESEARCH DESIGN AND METHODS: Patients receiving moderately to highly emetogenic chemotherapy received dexamethasone (20 mg PO), ondansetron (16 mg IV) and either placebo or dronabinol (2.5 mg) prechemotherapy on day 1. Patients randomized to active treatment (dronabinol and/or ondansetron) also received dronabinol (2.5 mg) after chemotherapy on day 1. On day 2, fixed doses of placebo, dronabinol (10 mg), ondansetron (16 mg), or combination therapy were administered. On days 3-5, patients received placebo, flexible doses of dronabinol (10-20 mg), ondansetron (8-16 mg), or dronabinol and ondansetron (10-20 mg dronabinol, 8-16 mg ondansetron). MAIN OUTCOME MEASURES: Total response (TR = nausea intensity <5 mm on visual analog scale, no vomiting/retching, no rescue antiemetic), nausea (occurrence and intensity) and vomiting/retching episodes. RESULTS: Sixty-four patients were randomized; 61 analyzed for efficacy. TR was similar with dronabinol (54%), ondansetron (58%), and combination therapy (47%) versus placebo (20%). Nausea absence was significantly greater in active treatment groups (dronabinol, 71%; ondansetron, 64%; combination therapy, 53%) versus placebo (15%; p < 0.05 vs. placebo for all). Nausea intensity and vomiting/retching were lowest in patients treated with dronabinol. Active treatments were well tolerated. The low number of patients due to slow enrollment limits the interpretation of these data. CONCLUSIONS: Dronabinol or ondansetron was similarly effective for the treatment of CINV. Combination therapy with dronabinol and ondansetron was not more effective than either agent alone. Active treatments were well tolerated.

Integrity signals

Registry

Crossref · 10.1185/030079907x167525

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only one RCT has compared cannabinoids to a guideline medication (ondansetron) for CINV prevention.

    “Only one RCT has compared cannabinoids to a guideline medication (ondansetron) for CINV prevention [95] and none compared them to new generation drugs (5-HT3- or NK1 antagonists or neuroleptics) [94].”

    From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [95]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H.-M., & Baranowski, V.
Affiliations
  • Bethesda Hospital East (US)
  • Compassionate Cancer Care (US)
  • Duke Medical Center (US)
  • Solvay (United States) (US)
Corresponding author
Meiri, Eyal
ORCID
Vredenburgh, James J.
Venue
Current Medical Research and Opinion
Publisher
Informa Healthcare
Published
2007-02-01
Volume
23
Issue
3
Pages
533-543
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
DOI
10.1185/030079907x167525
OpenAlex
W2053215778
Cited by
214
References
24
Citations by year
2025: 10 · 2024: 17 · 2023: 9 · 2022: 21 · 2021: 16 · 2020: 15 · 2019: 18 · 2018: 18 · 2017: 12 · 2016: 15 · 2015: 13 · 2014: 7 · 2013: 8 · 2012: 8
FWCI
7.97
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Nausea and vomiting management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
dronabinol, ondansetron, combination antiemetic therapy, cannabinoids, antiemetic efficacy, tolerability, dexamethasone
MeSH terms
Adolescent, Adult, Analysis of Variance, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nausea, Neoplasms, Probability, Reference Values, Dronabinol, Vomiting, Treatment Outcome, Ondansetron, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review